Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT07330609
Recruiting Not applicable

Clinical, Radiographic, and Digital Evaluation of the Effects of Autogenous Grafts on Peri-implant Mucosa

NCT07330609 · tracked via the Priya Life Science Turkey tracker
Sponsor
Kutahya Health Sciences University
Phase
Not applicable
Started
2026-02-02
Last updated
2026-07-28

Condition(s) studied

Peri-implant HealthFree Gingival GraftPeri-implant Mucositis

Investigational drug(s) / intervention(s)

Coronal palatal tissueApical palatal tissue

Coronal palatal tissue: This group will receive palatal grafts including marginal and interdental gingiva. This coronal palatal tissue will be applied to the peri-implant tissue at the second-stage implant surgery.

Apical palatal tissue: This group will receive palatal grafts harvested from approximately 1.5 mm apical to the gingival margin. This graft will be applied to the peri-implant tissue at the second-stage implant surgery.

Study summary

This study aims to evaluate the effects of autogenous grafts harvested from different palatal regions on the peri-implant mucosa when applied during second-stage dental implant surgery.

Clinical, radiographic, and digital assessment methods will be used to investigate the early effects of these grafts on peri-implant mucosal width and thickness. In addition, peri-implant tissue health and patient-reported outcomes will be evaluated to compare the effectiveness of the grafting techniques in peri-implant soft tissue management.

Eligibility

Sex
ALL
Min age
18 Months
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age over 18 years * Systemically healthy patients * Presence of premolar or molar tooth loss in the mandible * Adequate mesiodistal and interocclusal space for implant and restoration placement * At least four months elapsed since tooth extraction * Alveolar bone width of at least 6 mm and sufficient alveolar bone height to allow implant placement without compromising anatomical structures * Full-mouth plaque and bleeding scores less than 20% * Presence of opposing teeth in occlusion * Keratinized mucosa width in the relevant region less than 2 mm * Keratinized mucosa thickness in the relevant region of 2 mm or less * Presence of a healthy second premolar in the maxilla * Provision of written informed consent and permission for the use of data for research purposes Exclusion Criteria: * Poor oral hygiene * Uncontrolled periodontal disease * Pregnancy or lactation at any stage of the study * Uncontrolled diabetes mellitus * Immunocompromised patients * Previous radiotherapy to the head and neck region * Diseases or medications affecting bone metabolism * Antibiotic use within the three months prior to the procedure * Smoking more than 10 cigarettes per day * Pre- or simultaneous bone augmentation prior to implant placement * Lack of primary stability at the time of implant placement

Primary outcome measure(s)

  • Peri-implant Mucosal Thickness — Pre-operative and post-operative (before implant placement, 3rd month (second-stage implant surgery), 6th month after implant placement, and 12th month after prosthetic loading)
    The primary outcome is the change in peri-implant mucosal thickness measured at four time points using clinical and digital methods.

Trial sites (1)

FacilityCityRegionStatus
Kutahya Health Sciences University Kütahya Merkez Recruiting

More Kutahya Health Sciences University trials in Turkey

Nurse-Led Caregiver Support Program in Home Palliative Care Recruiting
Evaluation of Hydrogel Application in the Treatment of Periodontitis and Peri-implantitis Active, not recruiting
VALIDITY AND RELIABILITY OF THE TURKISH VERSION OF THE SEX PAIN QUESTIONNAIRE Enrolling by invitation
Effects of Neurodynamic and Carpal Bone Mobilization in Mild-to-Moderate Carpal Tunnel Syndrome Starting soon
Assessment of Early Healing Period of Dental Implants Active, not recruiting

Other trials for the same condition

Short Versus Standard Dental Implants: Clinical and Biomarker Outcomes Starting soon
Impact of Keratinized Mucosa Augmentation on Treatment Outcomes of Peri-implant Mucositis Recruiting
Impact of Smoking on Immune Responses in Peri-implant Health and Disease Recruiting
Effect of Modified Free Gingival Graft and Conventional Free Gingival Graft on Gingival Recession Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07330609 on ClinicalTrials.gov ↗ ← All trials in Turkey